Last Updated: September 25, 2026

Bionpharma Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for BIONPHARMA

BIONPHARMA has seventy-nine approved drugs.

There are five US patents protecting BIONPHARMA drugs.

Summary for Bionpharma
US Patents:5
Tradenames:73
Ingredients:68
NDAs:79
Patent Litigation for Bionpharma: See patent lawsuits for Bionpharma

Drugs and US Patents for Bionpharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bionpharma IVABRADINE HYDROCHLORIDE ivabradine hydrochloride TABLET;ORAL 213276-002 Sep 5, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial
Bionpharma GRANISETRON HYDROCHLORIDE granisetron hydrochloride INJECTABLE;INJECTION 078863-001 Jun 30, 2008 AP RX No No ⤷  Start Trial ⤷  Start Trial
Bionpharma BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride SYRUP;ORAL 203997-001 Sep 30, 2020 AA RX No No ⤷  Start Trial ⤷  Start Trial
Bionpharma CIMETIDINE cimetidine TABLET;ORAL 218220-003 Nov 7, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial
Bionpharma SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 204135-001 Jun 24, 2024 AA RX No No ⤷  Start Trial ⤷  Start Trial
Bionpharma DROXIDOPA droxidopa CAPSULE;ORAL 213033-002 Apr 28, 2021 AB RX No No ⤷  Start Trial ⤷  Start Trial
Bionpharma DROXIDOPA droxidopa CAPSULE;ORAL 213033-003 Apr 28, 2021 AB RX No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bionpharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bionpharma MIDOL LIQUID GELS ibuprofen CAPSULE;ORAL 021472-001 Oct 18, 2002 6,251,426 ⤷  Start Trial
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 11,090,280 ⤷  Start Trial
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 10,028,925 ⤷  Start Trial
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 9,693,978 ⤷  Start Trial
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 10,022,344 ⤷  Start Trial
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 9,693,979 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Bionpharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0984957 122012000017 Germany ⤷  Start Trial PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
1411900 SPC/GB11/015 United Kingdom ⤷  Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1613288 PA2011010 Lithuania ⤷  Start Trial PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317
3185856 CR 2024 00001 Denmark ⤷  Start Trial PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT. REG. NO/DATE: 66650 20230704; FIRST REG. NO/DATE: NL RVG 128835 20230216
1519731 13C0067 France ⤷  Start Trial PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1427415 2011/032 Ireland ⤷  Start Trial PRODUCT NAME: APIXABAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/11/691/001-005 20110518
2498758 301040 Netherlands ⤷  Start Trial PRODUCT NAME: METFORMINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; SAXAGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1401 20191113
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.